PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Brain Res. Author manuscript; available in PMC 2017 September 15.
Published in final edited form as:
PMCID: PMC5003702
NIHMSID: NIHMS771722

Roles for RNA-binding proteins in development and disease

Abstract

RNA-binding protein activities are highly regulated through protein levels, intracellular localization, and post-translation modifications. During development, mRNA processing of specific gene sets is regulated through manipulation of functional RNA-binding protein activities. The impact of altered RNA-binding protein activities also affects human diseases in which there are either a gain-of-function or loss-of-function causes pathogenesis. We will discuss RNA-binding proteins and their normal developmental RNA metabolism and contrast how their function is disrupted in disease.

Keywords: RNA-binding protein, RNA processing, Development, Neurodegenerative disease, Protein aggregate, Protein mis-regulation

1. Introduction

RNA-binding proteins (RBP) regulate RNA processing at multiple levels including alternative splicing, mRNA stability, mRNA localization and translation efficiency. As proteins highly involved in regulation, the expression of RBPs tends to be highly regulated. One mechanism of regulating the activities of RBPs in nuclear and cytoplasmic compartments is through changes in cellular localization. In the nucleus, some RBPs function as alternative splicing regulators often during development and/or in a tissue specific manner (Blencowe, 2006; Grabowski, 2011; Johnson, 2003; Wang et al., 2008). There are a growing number of examples in which alternative splicing changes have functional consequences (Giudice et al., 2014; Grabowski, 2011). In the cytoplasm, RBPs can function in the regulation of mRNA localization, mRNA stability or regulate the efficiency with which specific mRNAs are translated. As with the regulation of alternative splicing, regulation of cytoplasmic RNA processing events commonly occur during development (Jambor et al., 2015; Pilaz and Silver, 2015). The functions of RBPs can be disrupted in disease as either a primary cause of disease or a consequence. Understanding the normal roles of RBPs during periods of physiological change, such as during development, can reveal important aspects of function that are directly relevant to the pathogenic mechanisms and consequences in disease.

In this minireview, we discuss two sets of RBPs that control developmental transitions that are mis-regulated in disease: CUG-BP, Elav-like family (CELF) and Muscleblind-like (MBNL) proteins that have pathogenic roles in myotonic dystrophy (DM) and fused in sarcoma (FUS) and TAR DNA-binding protein (TDP-43) proteins that have pathogenic roles in amyotrophic lateral sclerosis (ALS). These RBPs are sequestered, hyperactive, or aggregated in the disease states. In the case of DM, the activities of both CELF and MBNL proteins revert to fetal patterns thereby promoting fetal mRNA processing of their targets in adult tissue. In neurons affected in ALS, FUS and TDP-43 are depleted from the nucleus and aggregate in the cytoplasm. Mutations in the FUS or TARDBP genes have a direct role in ALS pathogenesis; evidence also indicates that aggregation of FUS and TDP-43 causes both a loss-of-function and a gain-of-function. Currently, it is unknown if TDP-43 and FUS mRNA processing targets revert back to embryonic patterns; although it is clear there is mis-regulation of mRNA processing in ALS directly due to TDP-43 and FUS aggregation.

2. CELF and MBNL in DM

The CELF family contains six paralogs in humans and mice (CELF1-6), which can be subdivided into two groups containing CELF1-2 and CELF3-6 based on phylogenic analysis (Dasgupta and Ladd, 2012). Structurally, CELF proteins contain three RNA recognition motifs (RRMs) in which RRMs 1 and 2 are adjacent near the N-terminus, RRM3 is near the C-terminus and a unique domain of ~200 residues separates RRM2 and RRM3 (Ladd et al., 2004). CELF proteins bind preferentially to G/U-rich RNA sequence motifs (Faustino and Cooper, 2005; Marquis et al., 2006) and have well-established nuclear and cytoplasmic functions. In the nucleus, CELF proteins regulate alternative splicing to promote exon exclusion of some targets or inclusion of others (Kalsotra et al., 2008). Minigene and CLIP-seq studies have demonstrated that CELF proteins directly bind to pre-mRNAs, typically within introns, to promote the regulated splicing pattern (Daughters et al., 2009; Ladd et al., 2001; Wang et al., 2015). In the cytoplasm, CELF proteins affect mRNA translation or mRNA stability by binding the 3’UTR of the regulated mRNA (Blanc and Davidson, 2003; Subramaniam et al., 2008; Vlasova and Bohjanen, 2008; Zhang et al., 2008).

The MBNL family consists of three paralogs: MBNL1-3 (Kanadia et al., 2003a). MBNL proteins bind RNA through two pairs of zinc finger domains, which consist of CCCH amino acid residues (Begemann et al., 1997). MBNL proteins bind to YGCY motifs, preferring UGCU (Du et al., 2010; Goers et al., 2010). As regulators of alternative splicing both CELF and MBNL proteins typically bind to the introns downstream or upstream of an alternative exon to promote inclusion or exclusion, respectively (Kalsotra et al., 2008; Wang et al., 2012). In the cytoplasm, MBNL affects mRNA localization or stability by binding the 3’ UTR of target mRNAs (Llamusi et al., 2013; Masuda et al., 2012).

CELF and MBNL have overlapping targets for alternative splicing and mRNA stability, and are most often antagonistic regulators of these common targets (Masuda et al., 2012; Wang et al., 2015). As splicing regulators, CELF and MBNL proteins promote the opposite effects on splice site or exon usage. Global analysis of CLIP-seq data shows that CELF and MBNL proteins overlap with thousands of 3’ UTR targets and affect mRNA stability (Wang et al., 2015). CELF-bound mRNA targets are degraded while MBNL1 binding leads to mRNA localization to the membrane for translation (Wang et al., 2015).

2.1 Development

During development, changes in the abundance and localization of CELF and MBNL proteins have been shown to promote global splicing transitions (Kalsotra et al., 2008). CELF and cytoplasmic MBNL protein levels are high in embryonic mouse skeletal muscle and CELF protein levels decrease while MBNL localizes to the nucleus during postnatal development (Kalsotra et al., 2008; Lin et al., 2006). CELF protein levels also drop during mouse heart postnatal development while MBNL protein levels increase (Kalsotra et al., 2008). Therefore in both striated muscles, the nuclear activities of CELF and MBNL proteins change in opposite directions. Studies of the developmental effects of CELF and MBNL proteins have focused on alternative splicing transitions in striated muscle. There are also likely to be important cytoplasmic effects during development that remain to be identified. The genes that undergo the developmental splicing transition are enriched for vesicular trafficking, among other functional categories, and induced CELF1 expression in transgenic mice reverts a subset of vesicular trafficking genes to the fetal splicing pattern (Giudice et al., 2014). MBNL proteins have been shown to maintain the differentiated state in cells relevant to brain and muscle, by repressing embryonic stem cell alternative splicing pattern (Han et al., 2013).

Interestingly, the dramatic drop in CELF protein levels during heart development is not due to a corresponding drop in mRNA levels (Kalsotra et al., 2008). CELF protein down regulation is regulated by at least two mechanisms. First, CELF translation is repressed postnatally due to up-regulation of microRNAs (miRNAs) including miR-23a/b. Second CELF1 protein is dephosphorylated during postnatal development resulting in protein destabilization (Kalsotra et al., 2010; Kuyumcu-Martinez et al., 2007).

2.2 Disease - DM

DM is an autosomal dominant disease that affects multiple organ systems including skeletal muscle, heart and brain. DM is the most common form on of adult-onset muscular dystrophy and the second most common form of muscular dystrophy overall. Mutations in two different genes cause different forms of DM: DM type 1 (DM1) and DM type 2 (DM2). DM1 is caused by an expansion of a CTG repeat in the 3’ UTR in the DMPK gene, and DM2 is caused by a CCTG repeat in intron 1 of the CNBP gene (Brook et al., 1992; Ranum et al., 1998). Unaffected individuals contain fewer than 34 repeats in the DMPK gene while affected individuals have from 80 to thousands of repeats. In both DM1 and DM2, the expanded allele is transcribed and the expanded repeat within the RNA forms a hairpin structure and aggregates into nuclear foci (Napierała and Krzyzosiak, 1997). MBNL proteins are sequestered on the RNA foci substantially reducing the pool of functional protein and interfering with normal MBNL function (Kanadia et al., 2003b; Kanadia et al., 2006; Miller et al., 2000). In addition, PKC is activated by an unknown mechanism which phosphorylates and stabilizes CELF1 proteins and results in increased CELF1 function (Kuyumcu-Martinez et al., 2007). Increased CELF and decreased MBNL function revert the splicing patterns back to the splicing pattern seen in fetal tissue (Charlet-B et al., 2002; Philips et al., 1998; Savkur et al., 2001).

Mis-regulated mRNA processing by CELF and MBNL proteins has been linked to predominant symptoms in DM and DM1 in particular. The best characterized is aberrant splicing of the muscle-specific chloride channel (CLCN1) which has been demonstrated to cause the myotonia for which the disease is named (Charlet-B et al., 2002; Mankodi et al., 2002). MBNL1 knockout mice and compound loss of the two MBNL paralogs expressed in striated muscle (Mbnl1−/−, Mbnl2+/−) produce phenotypes consistent with DM, including dramatic tissue pathology and mis-regulated alternative splicing including Clcn1, supporting the role of MBNL loss of function in disease pathogenesis (Kanadia et al., 2003b; Lee et al., 2013). The mis-regulation of insulin receptor alternative splicing correlates with insulin resistance seen in patients (Savkur et al., 2001; Sen et al., 2010). Muscle weakness has been correlated with numerous splicing changes in DM1 (Nakamori et al., 2013). One particular example, CACNA1S (CaV1.1) exon 29 is antagonistically regulated by MBNL1 and CELF1 and associated with muscle weakness (Tang et al., 2012). Muscle pathology is also linked to mis-regulation of CELF1 mRNA translation targets (Jones et al., 2012). Another clinical feature of DM1 is altered cognition. Mis-splicing of MBNL targets have been identified in brains of Mbnl2 knockout mice (Charizanis et al., 2012; Goodwin et al., 2015). The clinical features associated with expression of fetal isoforms and reversion of cytoplasmic functions to fetal patterns has demonstrated the necessity of the developmental transitions for normal function in adult tissues.

3. FUS and TDP-43 in ALS

Familial forms of ALS are caused by mutations in a large and growing number of genes. Here we highlight TDP-43 and FUS proteins as they are linked to ALS pathogenesis independent of mutations present in the TARDBP or FUS genes, respectively (Giordana et al., 2010; Neumann et al., 2006; Neumann et al., 2009).

3.1 Normal roles of TDP-43 and FUS

TDP-43 is a DNA- and RNA-binding protein with both cytoplasmic and nuclear functions. TDP-43 contains two RRMs, a nuclear localization signal (NLS), nuclear export signal (NES), and a glycine-rich domain (GRD) (Fiesel and Kahle, 2011). TDP-43 is predominantly but not exclusively localized to the nucleus and depending upon its localization has functions in mRNA metabolism including alternative splicing, mRNA stability, and miRNA biogenesis (Buratti et al., 2010; Polymenidou et al., 2011; Volkening et al., 2009). Homozygous knockout of TDP-43 (Tardbp−/−) is embryonic lethal at E3.5 to E8.5 demonstrating a requirement for early embryonic development (Kraemer et al., 2010; Sephton et al., 2010). Similar to expression of CELF1 during heart development, TDP-43 protein levels decrease during mouse brain postnatal development while TDP-43 mRNA levels remain constant (Huang et al., 2010; Sephton et al., 2010). The mechanism of TDP-43 down regulation during development is unknown. The developmental targets of TDP-43 is also currently unknown.

FUS was identified as an oncogenic fusion protein that along with EWSR1 and TAF15 make up the FET family of proteins (Crozat et al., 1993)(Wu et al., 2009). Similar to TDP-43, FUS contains a NES, NLS, GRD, and a single RRM (Fiesel and Kahle, 2011). FUS is a DNA- and RNA-binding protein with evidence for functions in DNA repair, transcriptional regulation, alternative splicing regulation, RNA localization, and association with stress granules (Sama et al., 2014). FUS has also been shown to couple transcription to alternative splicing by interacting with both RNA polymerase II and U1 snRNP (Yu and Reed, 2015). Homozygous knockout of Fus produces perinatal lethality in inbred mouse lines (Hicks et al., 2000). However, Fus knockout animals survived in an outbred strain, but developed neurodegenerative pathology (Kino et al., 2015). During postnatal development, FUS protein levels decrease in brain, skeletal muscle, heart, and liver tissue while mRNA levels remain constant (Huang et al., 2010). Similar to the current state of knowledge for TDP-43, the developmental targets of FUS and how FUS-dependent mRNA regulation affects development remain to be determined.

3.2 Disease – ALS

ALS is a neurodegenerative disease that affects motor neurons resulting in rapidly progressive loss of muscle function. Ninety percent of ALS cases are sporadic; however the familial forms of ALS in which is disease is dominantly inherited provides insight into mechanisms of pathogenesis.

Involvement of TDP-43 and FUS in ALS pathogenesis has been discussed in several excellent reviews (Fiesel and Kahle, 2011; Lourenco et al., 2015; Orozco and Edbauer, 2013; Polymenidou et al., 2012). A critical pathological effect in ALS (and other neurodegenerative diseases) is aggregate formation of TDP-43 and FUS in the cytoplasm and depletion of these proteins from the nucleus (Giordana et al., 2010; Kwiatkowski et al., 2009; Neumann et al., 2009). A recent and important proposal is that the protein aggregates found in ALS have prion-like qualities and reflect an anomaly of the normal protein-protein interactions required for the dynamic nature of RNA metabolism. TDP-43 and FUS, as well as other RBPs shown to have pathogenic effects in ALS, contain prion-like domains (Gitler and Shorter, 2011; King et al., 2012). Furthermore, mutations in these genes that cause ALS accelerate the prion-like domain’s ability to self-seed (Kim et al., 2013; Shorter and Taylor, 2013).

Recent work suggests that both loss and gain of TDP-43 and FUS functions contribute to ALS pathogenesis, however, the specific mechanisms and functional consequences are as yet unclear. Loss of TDP-43 causes inclusion of non-conserved, cryptic exons leading to non-sense mediated decay of TDP-43 splicing targets (Ling et al., 2015). In addition, cytoplasmic aggregation of TDP-43 is likely to affect its function in transporting mRNA as mRNP granules (Alami et al., 2014). Coexpression of TDP-43 with FMRP, with which TDP-43 forms a complex involved in transport of mRNPs, prevents TDP-43 aggregation and restores appropriate translation (Coyne et al., 2015). Loss of TDP-43 in mice causes age-dependent progressive motor neuron degeneration indicating that loss of TDP-43 activity is consistent with features of ALS (Wu et al., 2012; Yang et al., 2014)’. Mutated FUS seen in ALS patients causes a loss of interaction between FUS and U1 snRNP (Sun et al., 2015) suggesting the potential for pathogenic effects via disrupted co-transcriptional RNA processing. Although FUS loss does not cause lethality, it causes a unique neurodegenerative phenotype distinctive from ALS, which indicates that FUS loss-of-function is disruptive to normal neural function but may not be the driving force of ALS pathogenesis (Kino et al., 2015). FUS gains function through mutations that have a greater association with SMN protein in the cytoplasm (Sun et al., 2015). In addition, SOD1, another ALS-associated protein, is misfolded in familial ALS patients with mutations in FUS or TDP-43 and can be misfolded just by the overexpression of wildtype FUS or TDP-43 (Pokrishevsky et al., 2012).

4. Conclusion

CELF and MBNL proteins illustrate that RBPs are highly regulated during development to perform both nuclear and cytoplasmic functions and that both functions are disrupted in diseases that affect the activities of the proteins. TDP43 and FUS illustrate that RBP functions require dynamic interactions between proteins and RNA within transient complexes and that disruption of proper association-dissociation leads to pathogenesis (Fig. 1). It is well established that CELF1 and MBNL1 activities revert to the fetal pattern and shift a regulatory program such that functions required in adult tissues are lost. In the examples of MBNL1, TDP-43, and FUS, the level of protein is not strongly altered but rather the functionality of the protein is affected. This highlights that different effects on protein function including localization, temporal expression, or amount of protein can result in pathogenicity.

Fig. 1
Protein levels and subcellular localization of RBPs during development and disease. (A) CELF1 (blue) is regulated by phosphorylation and microRNAs while MBNL1 (red) localization changes during development. In DM, the presence of DMPK expanded CUG-repeat ...

Further investigation is required to fully understand the normal balance of RNA-binding protein function and the disruption of the function that leads to disease. Some functions of CELF and MBNL proteins during development are well established, but because studies have primarily focused on splicing regulation during development and its disruption in disease, there is likely to be important roles for these proteins in other aspects of RNA metabolism. Less is known about the functions of FUS and TDP-43 during development. An understanding of the functions of these RNA binding proteins in development will provide insight into their roles during disease pathogenesis.

Highlights

  • RBPs can be developmentally regulated for normal RNA metabolism.
  • RBPs are mis-regulated in certain diseases (e.g. DM and ALS).
  • This minireview stresses the importance of proper RBP level and localization.

Acknowledgments

Funding to this laboratory is provided by the Muscular Dystrophy Association and the NIH (R01 HL045565, R01 AR45653, R01 AR060733).

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • Alami NH, Smith RB, Carrasco MA, Williams LA, Winborn CS, Han S, Kiskinis E, Winborn B, Freibaum BD, Kanagaraj A, Clare AJ, Badders NM, Bilican B, Chaum E, Chandran S, Shaw CE, Eggan KC, Maniatis T, Taylor PJ. Axonal Transport of TDP-43 mRNA Granules Is Impaired by ALS-Causing Mutations. Neuron. 2014;81:536–543. [PMC free article] [PubMed]
  • Begemann G, Paricio N, Artero R, Kiss I, Perez-Alonso M, Mlodzik M. muscleblind, a gene required for photoreceptor differentiation in Drosophila, encodes novel nuclear Cys3His-type zinc-finger-containing proteins. Development. 1997;124:4321–4331. [PubMed]
  • Blanc V, Davidson NO. C-to-U RNA editing: mechanisms leading to genetic diversity. J. Biol. Chem. 2003;278:1395–1398. [PubMed]
  • Blencowe BJ. Alternative splicing: new insights from global analyses. Cell. 2006;126:37–47. [PubMed]
  • Brook J, McCurrach M, Harley H, Buckler A, Church D, Aburatani H, Hunter K, Stanton V, Thirion J, Hudson T. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell. 1992;69:385. [PubMed]
  • Buratti E, Conti DL, Stuani C, Romano M, Baralle M, Baralle F. Nuclear factor TDP- 43 can affect selected microRNA levels. FEBS J. 2010;227:2268–2281. [PubMed]
  • Charizanis K, Lee K-YY, Batra R, Goodwin M, Zhang C, Yuan Y, Shiue L, Cline M, Scotti MM, Xia G, Kumar A, Ashizawa T, Clark HB, Kimura T, Takahashi MP, Fujimura H, Jinnai K, Yoshikawa H, Gomes-Pereira M, Gourdon G, Sakai N, Nishino S, Foster TC, Ares M, Darnell RB, Swanson MS. Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy. Neuron. 2012;75:437–450. [PMC free article] [PubMed]
  • Charlet-B N, Savkur RS, Singh G, Philips AV, Grice EA, Cooper TA. Loss of the Muscle-Specific Chloride Channel in Type 1 Myotonic Dystrophy Due to Misregulated Alternative Splicing. Mol. Cell. 2002;10:45–53. [PubMed]
  • Coyne AN, Yamada SB, Siddegowda BB, Estes PS, Zaepfel BL, Johannesmeyer JS, Lockwood DB, Pham LT, Hart MP, Cassel JA, Freibaum B, Boehringer AV, Taylor JP, Reitz AB, Gitler AD, Zarnescu DC. Fragile X protein mitigates TDP-43 toxicity by remodeling RNA granules and restoring translation. Hum. Mol. Genet. 2015;24:6886–6898. [PMC free article] [PubMed]
  • Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature. 1993;363:640–644. [PubMed]
  • Dasgupta T, Ladd AN. The importance of CELF control: molecular and biological roles of the CUG-BP, Elav-like family of RNA-binding proteins. Wiley Interdiscip. Rev. RNA. 2012;3:104–121. [PMC free article] [PubMed]
  • Daughters RS, Tuttle DL, Gao W, Ikeda Y, Moseley ML, Ebner TJ, Swanson MS, Ranum LP. RNA gain-of-function in spinocerebellar ataxia type 8. PLoS Genet. 2009;5 [PMC free article] [PubMed]
  • Du H, Cline MS, Osborne RJ, Tuttle DL, Clark TA, Donohue JP, Hall MP, Shiue L, Swanson MS, Thornton CA, Ares M. Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nature Struct. Mol. Biol. 2010;17:187–193. [PMC free article] [PubMed]
  • Faustino NA, Cooper TA. Identification of putative new splicing targets for ETR-3 using sequences identified by systematic evolution of ligands by exponential enrichment. Mol. Cell. Biol. 2005;25:879–887. [PMC free article] [PubMed]
  • Fiesel FC, Kahle PJ. TDP- 43 and FUS/TLS: cellular functions and implications for neurodegeneration. FEBS J. 2011;278:3550–3568. [PubMed]
  • Giordana MT, Piccinini M, Grifoni S, De Marco G, Vercellino M, Magistrello M, Pellerino A, Buccinna B, Lupino E, Rinaudo MT. TDP- 43 redistribution is an early event in sporadic amyotrophic lateral sclerosis. Brain Pathol. 2010;20:351–360. [PubMed]
  • Gitler AD, Shorter J. RNA-binding proteins with prion-like domains in ALS and FTLD-U. Prion. 2011;5:179–187. [PMC free article] [PubMed]
  • Giudice J, Xia Z, Wang ET, Scavuzzo MA, Ward AJ, Kalsotra A, Wang W, Wehrens XH, Burge CB, Li W, Cooper TA. Alternative splicing regulates vesicular trafficking genes in cardiomyocytes during postnatal heart development. Nature communications. 2014;5:3603. [PMC free article] [PubMed]
  • Goers ES, Purcell J, Voelker RB, Gates DP, Berglund JA. MBNL1 binds GC motifs embedded in pyrimidines to regulate alternative splicing. Nucleic Acids Res. 2010;38:2467–2484. [PMC free article] [PubMed]
  • Goodwin M, Mohan A, Batra R, Lee K-YY, Charizanis K, Gómez FJ, Eddarkaoui S, Sergeant N, Buée L, Kimura T, Clark HB, Dalton J, Takamura K, Weyn-Vanhentenryck SM, Zhang C, Reid T, Ranum LP, Day JW, Swanson MS. MBNL Sequestration by Toxic RNAs and RNA Misprocessing in the Myotonic Dystrophy Brain. Cell Rep. 2015;12:1159–1168. [PMC free article] [PubMed]
  • Grabowski P. Alternative splicing takes shape during neuronal development. Current opinion in genetics & development. 2011;21:388–394. [PubMed]
  • Han H, Irimia M, Ross PJ, Sung H-KK, Alipanahi B, David L, Golipour A, Gabut M, Michael IP, Nachman EN, Wang E, Trcka D, Thompson T, O'Hanlon D, Slobodeniuc V, Barbosa-Morais NL, Burge CB, Moffat J, Frey BJ, Nagy A, Ellis J, Wrana JL, Blencowe BJ. MBNL proteins repress ES-cell-specific alternative splicing and reprogramming. Nature. 2013;498:241–245. [PMC free article] [PubMed]
  • Hicks GG, Singh N, Nashabi A, Mai S, Bozek G, Klewes L, Arapovic D, White EK, Koury MJ, Oltz EM, Van Kaer L, Ruley HE. Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death. Nat. Genet. 2000;24:175–179. [PubMed]
  • Huang C, Xia PY, Zhou H. Sustained expression of TDP-43 and FUS in motor neurons in rodent's lifetime. Int. J. Biol. Sci. 2010;6:396–406. [PMC free article] [PubMed]
  • Jambor H, Surendranath V, Kalinka AT, Mejstrik P, Saalfeld S, Tomancak P. Systematic imaging reveals features and changing localization of mRNAs in Drosophila development. eLife. 2015;4 [PMC free article] [PubMed]
  • Johnson JM. Genome-Wide Survey of Human Alternative Pre-mRNA Splicing with Exon Junction Microarrays. Science. 2003;302:2141–2144. [PubMed]
  • Jones K, Wei C, Iakova P, Bugiardini E, Schneider-Gold C, Meola G, Woodgett J, Killian J, Timchenko NA, Timchenko LT. GSK3β mediates muscle pathology in myotonic dystrophy. J. Clin. Invest. 2012;122:4461–4472. [PMC free article] [PubMed]
  • Kalsotra A, Xiao X, Ward AJ, Castle JC, Johnson JM, Burge CB, Cooper TA. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proceedings of the National Academy of Sciences. 2008;105:20333–20338. [PubMed]
  • Kalsotra A, Wang K, Li P-F, Cooper TA. MicroRNAs coordinate an alternative splicing network during mouse postnatal heart development. Genes Dev. 2010;24:653–658. [PubMed]
  • Kanadia R, Urbinati C, Crusselle V, Luo D, Lee Y-J, Harrison J, Oh S, Swanson M. Developmental expression of mouse muscleblind genes Mbnl1, Mbnl2 and Mbnl3. Gene Expr. Patterns. 2003a;3:459–462. [PubMed]
  • Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, Esson D, Timmers AM, Hauswirth WW, Swanson MS. A Muscleblind Knockout Model for Myotonic Dystrophy. Science. 2003b;302:1978–1980. [PubMed]
  • Kanadia RN, Shin J, Yuan Y, Beattie SG, Wheeler TM, Thornton CA, Swanson MS. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc. Natl. Acad. Sci. U. S. A. 2006;103:11748–11753. [PubMed]
  • Kim HJ, Kim NC, Wang Y-DD, Scarborough EA, Moore J, Diaz Z, MacLea KS, Freibaum B, Li S, Molliex A, Kanagaraj AP, Carter R, Boylan KB, Wojtas AM, Rademakers R, Pinkus JL, Greenberg SA, Trojanowski JQ, Traynor BJ, Smith BN, Topp S, Gkazi A-SS, Miller J, Shaw CE, Kottlors M, Kirschner J, Pestronk A, Li YR, Ford AF, Gitler AD, Benatar M, King OD, Kimonis VE, Ross ED, Weihl CC, Shorter J, Taylor JP. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495:467–473. [PMC free article] [PubMed]
  • King OD, Gitler AD, Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res. 2012;1462:61–80. [PMC free article] [PubMed]
  • Kino Y, Washizu C, Kurosawa M, Yamada M, Miyazaki H, Akagi T, Hashikawa T, Doi H, Takumi T, Hicks GG, Hattori N, Shimogori T, Nukina N. FUS/TLS deficiency causes behavioral and pathological abnormalities distinct from amyotrophic lateral sclerosis. Acta Neuropathol. Commun. 2015;3:24. [PMC free article] [PubMed]
  • Kraemer BC, Schuck T, Wheeler JM, Robinson LC, Trojanowski JQ, Lee VM, Schellenberg GD. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta. Neuropathol. 2010;119:409–419. [PMC free article] [PubMed]
  • Kuyumcu-Martinez NM, Wang G-S, Cooper TA. Increased Steady-State Levels of CUGBP1 in Myotonic Dystrophy 1 Are Due to PKC-Mediated Hyperphosphorylation. Mol. Cell. 2007;28:68–78. [PMC free article] [PubMed]
  • Kwiatkowski TJ, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, Valdmanis P, Rouleau GA, Hosler BA, Cortelli P, de Jong PJ, Yoshinaga Y, Haines JL, Pericak-Vance MA, Yan J, Ticozzi N, Siddique T, McKenna-Yasek D, Sapp PC, Horivitz HR, Landers JE, Brown RHJ. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205–1208. [PubMed]
  • Ladd AN, Charlet N, Cooper TA. The CELF family of RNA binding proteins is implicated in cell-specific and developmentally regulated alternative splicing. Molecular and Cellular Biology. 2001;21:1285–1296. [PMC free article] [PubMed]
  • Ladd AN, Nguyen NH, Malhotra K, Cooper TA. CELF6, a member of the CELF family of RNA-binding proteins, regulates muscle-specific splicing enhancer-dependent alternative splicing. The Journal of biological chemistry. 2004;279:17756–17764. [PubMed]
  • Lee K-YY, Li M, Manchanda M, Batra R, Charizanis K, Mohan A, Warren SA, Chamberlain CM, Finn D, Hong H, Ashraf H, Kasahara H, Ranum LP, Swanson MS. Compound loss of muscleblind-like function in myotonic dystrophy. EMBO Mol. Med. 2013;5:1887–1900. [PMC free article] [PubMed]
  • Lin X, Miller J, Mankodi A, Kanadia R, Yuan Y, Moxley R, Swanson M, Thornton C. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum. Mol. Genet. 2006;15:2087–2097. [PubMed]
  • Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349:650–655. [PMC free article] [PubMed]
  • Liu Y, Atkinson RA, Fernandez-Martos CM, Kirkcaldie MT, Cui H, Vickers JC, King AE. Changes in TDP-43 expression in development, aging, and in the neurofilament light protein knockout mouse. Neurobiol. Aging. 2015;36:1151–1159. [PubMed]
  • Llamusi B, Bargiela A, Fernandez-Costa JM, Garcia-Lopez A, Klima R, Feiguin F, Artero R. Muscleblind, BSF and TBPH are mislocalized in the muscle sarcomere of a Drosophila myotonic dystrophy model. Dis. Models Mech. 2013;6:184–196. [PMC free article] [PubMed]
  • Lourenco GF, Janitz M, Huang Y, Halliday GM. Long noncoding RNAs in TDP-43 and FUS/TLS-related frontotemporal lobar degeneration (FTLD) Neurobiol. Dis. 2015;82:445–454. [PubMed]
  • Mankodi A, Takahashi MP, Jiang H, Beck CL, Bowers WJ, Moxley RT, Cannon SC, Thornton CA. Expanded CUG Repeats Trigger Aberrant Splicing of ClC-1 Chloride Channel Pre-mRNA and Hyperexcitability of Skeletal Muscle in Myotonic Dystrophy. Mol. Cell. 2002;10:35–44. [PubMed]
  • Marquis J, Paillard L, Audic Y, Cosson B, Danos O, Le Bec C, Osborne HB. CUG-BP1/CELF1 requires UGU-rich sequences for high-affinity binding. The Biochemical journal. 2006;400:291–301. [PubMed]
  • Masuda A, Andersen HS, Doktor TK, Okamoto T, Ito M, Andresen BS, Ohno K. CUGBP1 and MBNL1 preferentially bind to 3' UTRs and facilitate mRNA decay. Sci. Rep. 2012;2:209. [PMC free article] [PubMed]
  • Miller JW, Urbinati CR, Teng-umnuay P, Stenberg MG, Byrne BJ, Thornton CA, Swanson MS. Recruitment of human muscleblind proteins to (CUG)n expansions associated with myotonic dystrophy. EMBO J. 2000;19:4439–4448. [PubMed]
  • Nakamori M, Sobczak K, Puwanant A, Welle S, Eichinger K, Pandya S, Dekdebrun J, Heatwole CR, McDermott MP, Chen T, Cline M, Tawil R, Osborne RJ, Wheeler TM, Swanson MS, Moxley RT, Thornton CA. Splicing biomarkers of disease severity in myotonic dystrophy. Ann. Neurol. 2013;74:862–872. [PMC free article] [PubMed]
  • Napierała M, Krzyzosiak WJ. CUG repeats present in myotonin kinase RNA form metastable "slippery" hairpins. J. Biol. Chem. 1997;272:31079–31085. [PubMed]
  • Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130–133. [PubMed]
  • Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IR. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain. 2009;132:2922–2931. [PMC free article] [PubMed]
  • Orozco D, Edbauer D. FUS-mediated alternative splicing in the nervous system: consequences for ALS and FTLD. J. Mol. Med. (Berl) 2013;91:1343–1354. [PubMed]
  • Philips AV, Timchenko LT, Cooper TA. Disruption of Splicing Regulated by a CUG-Binding Protein in Myotonic Dystrophy. Science. 1998;280:737–741. [PubMed]
  • Pilaz L-JJ, Silver DL. Post-transcriptional regulation in corticogenesis: how RNA-binding proteins help build the brain. Wiley interdisciplinary reviews. RNA. 2015;6:501–515. [PMC free article] [PubMed]
  • Pokrishevsky E, Grad LI, Yousefi M, Wang J, Mackenzie IR, Cashman NR. Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. PloS One. 2012;7:e35050. [PMC free article] [PubMed]
  • Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling SC, Sun E, Wancewicz E, Mazur C, Kordasiewicz H, Sedaghat Y, Donohue JP, Shiue L, Bennett CF, Yeo GW, Cleveland DW. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nature Neurosci. 2011;14:459–468. [PMC free article] [PubMed]
  • Polymenidou M, Lagier-Tourenne C, Hutt KR, Bennett CF, Cleveland DW, Yeo GW. Misregulated RNA processing in amyotrophic lateral sclerosis. Brain Res. 2012;1462:3–15. [PMC free article] [PubMed]
  • Ranum LP, Rasmussen PF, Benzow KA, Koob MD, Day JW. Genetic mapping of a second myotonic dystrophy locus. Nat. Genet. 1998;19:196–198. [PubMed]
  • Sama R, Ward CL, Bosco DA. Functions of FUS/TLS From DNA Repair to Stress Response: Implications for ALS. ASN Neuro. 2014;6 [PMC free article] [PubMed]
  • Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat. Genet. 2001;29:40–47. [PubMed]
  • Sen S, Talukdar I, Liu Y, Tam J, Reddy S, Webster NJ. Muscleblind-like 1 (Mbnl1) promotes insulin receptor exon 11 inclusion via binding to a downstream evolutionarily conserved intronic enhancer. J. Biol. Chem. 2010;285:25426–25437. [PMC free article] [PubMed]
  • Sephton CF, Good SK, Atkin S, Dewey CM, Mayer P, Herz J, Yu G, Sephton CF, Good SK, Atkin S, Dewey CM, Mayer P, Herz J, Yu G. TDP-43 Is a Developmentally Regulated Protein Essential for Early Embryonic Development. J Biol. Chem. 2010;285:6826–6834. [PMC free article] [PubMed]
  • Shorter J, Taylor PJ. Disease mutations in the prion-like domains of hnRNPA1 and hnRNPA2/B1 introduce potent steric zippers that drive excess RNP granule assembly. Rare Dis. 2013;1:e25200. [PMC free article] [PubMed]
  • Subramaniam D, Natarajan G, Ramalingam S, Ramachandran I, May R, Queimado L, Houchen CW, Anant S. Translation inhibition during cell cycle arrest and apoptosis: Mcl-1 is a novel target for RNA binding protein CUGBP2. Am. J. Physiol. Gastrointest. Liver Physiol. 2008;294:32. [PubMed]
  • Sun S, Ling S-CC, Qiu J, Albuquerque CP, Zhou Y, Tokunaga S, Li H, Qiu H, Bui A, Yeo GW, Huang EJ, Eggan K, Zhou H, Fu X-DD, Lagier-Tourenne C, Cleveland DW. ALS-causative mutations in FUS/TLS confer gain and loss of function by altered association with SMN and U1-snRNP. Nature Commun. 2015;6:6171. [PMC free article] [PubMed]
  • Tang ZZ, Yarotskyy V, Wei L, Sobczak K, Nakamori M, Eichinger K, Moxley RT, Dirksen RT, Thornton CA. Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of Ca(V)1.1 calcium channel. Hum. Mol. Genet. 2012;21:1312–1324. [PMC free article] [PubMed]
  • Vlasova IA, Bohjanen PR. Posttranscriptional regulation of gene networks by GU-rich elements and CELF proteins. RNA Biol. 2008;5:201–207. [PMC free article] [PubMed]
  • Volkening K, Leystra-Lantz C, Yang W, Jaffee H, Strong MJ. Tar DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS) Brain Res. 2009;1305:168–182. [PubMed]
  • Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB. Alternative isoform regulation in human tissue transcriptomes. Nature. 2008;456:470–476. [PMC free article] [PubMed]
  • Wang ET, Cody NA, Jog S, Biancolella M, Wang TT, Treacy DJ, Luo S, Schroth GP, Housman DE, Reddy S, Lécuyer E, Burge CB. Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins. Cell. 2012;150:710–724. [PMC free article] [PubMed]
  • Wang ET, Ward AJ, Cherone JM, Giudice J, Wang TT, Treacy DJ, Lambert NJ, Freese P, Saxena T, Cooper TA, Burge CB. Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins. Genome Res. 2015;25:858–871. [PubMed]
  • Wu C, Orozco C, Boyer J, Leglise M, Goodale J, Batalov S, Hodge CL, Haase J, Janes J, Huss JW, Su AI. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol. 2009;10:R130. [PMC free article] [PubMed]
  • Wu L-S, Cheng W-C, Shen CK. Targeted depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in mice. J. Biol. Chem. 2012;287:27335–27344. [PMC free article] [PubMed]
  • Yang C, Wang H, Qiao T, Yang B, Aliaga L, Qiu L, Tan W, Salameh J, McKenna-Yasek D, Smith T, Peng L, Moore MJ, Brown RHJ, Cai H, Xu Z. Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2014;111:E1121–E1129. [PubMed]
  • Yu Y, Reed R. FUS functions in coupling transcription to splicing by mediating an interaction between RNAP II and U1 snRNP. Proc. Natl. Acad. Sci. U. S. A. 2015;112:8608–8613. [PubMed]
  • Zhang L, Lee JE, Wilusz J, Wilusz CJ. The RNA-binding protein CUGBP1 regulates stability of tumor necrosis factor mRNA in muscle cells: implications for myotonic dystrophy. J Biol. Chem. 2008;283:22457–22463. [PMC free article] [PubMed]